Showing results (431-440 of 1,390) with videos related to

Sort By:
Pageof 139
The Permanente Journal|March 1, 2017
Physicians' Perceptions of Volunteer Service at Safety-Net ClinicsLaura Mcgeehan, Michael A Takehara, Ellen Daroszewski
The Permanente Journal|March 1, 2017
The Grateful Aging Program: A Naturalistic Model of Transformation and Healing into the Second Half of LifeMarilyn Schlitz
The Permanente Journal|March 1, 2017
End-Stage Renal Disease Outcomes among the Kaiser Permanente Southern California Creatinine Safety Program (Creatinine SureNet): Opportunities to Reflect and ImproveJohn J Sim, Michael Batech, Kim N Danforth, et al.
The Permanente Journal|February 26, 2021
Effectiveness at 24 Months of Single-Source Generic Carbamazepine, Lamotrigine, or Levetiracetam in Newly Diagnosed Focal EpilepsySuresh Gurbani, Sirichai Chayasirisobhon, Aditya Gurbani, et al.
The Permanente Journal|February 26, 2021
Development and Validation of Machine Learning Models: Electronic Health Record Data To Predict Visual Acuity After Cataract SurgeryStacey E Alexeeff, Stephen Uong, Liyan Liu, et al.
The Permanente Journal|February 26, 2021
A Quality Improvement Initiative Targeting Chronic Kidney Disease Metrics Through Increased Urinary Albumin TestingKen J Park, Robert S Unitan, Micah L Thorp
The Permanente Journal|February 26, 2021
First Pass Recanalization Rates of Solitaire vs Trevo vs Primary Aspiration: The Kaiser Southern California ExperienceConrad W Liang, Harjyot J Toor, Evelin Duran Martinez, et al.
The Permanente Journal|February 26, 2021
The Application of Community-Based Information from the American Community Survey in a Large Integrated Health Care OrganizationZhi Liang, Claudia Nau, Fagen Xie, et al.
The Permanente Journal|February 26, 2021
Using the County Health Rankings Framework to Create National Percentile Scores for Health Outcomes and Health FactorsMatthew C Stiefel, Tasha Straszewski, Jennifer C Taylor, et al.
The Permanente Journal|February 26, 2021
Immune-related Adverse Effects Associated with Programmed Death-1 Inhibitor Therapy in the Treatment of Non-Small Cell Lung Cancer: Incidence, Management, and Effect on OutcomesTimothy Chiu, Christopher Yamamoto, Fang Niu, et al.
Pageof 139